The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib-Reference-Cited by-同舟云学术

The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib

Published:2021-02-17 Issue:4 Volume:22 Page:56-59
ISSN:1815-1442
Container-title:Journal of Modern Oncology
language:
Short-container-title:J. Mod. Onco.

Author:

Mazurina Natalya V.^ORCID,Artamonova Elena V.^ORCID,Beloyartseva Maria F.^ORCID,Volkova Ekaterina I.^ORCID,Ganshina Inna P.^ORCID,Troshina Ekaterina A.^ORCID,Tjulandin Sergey A.^ORCID,Chubenko Viacheslav A.^ORCID

Abstract

The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib was developed by the experts of the Russian Association of Endocrinologists and the Russian Society of Clinical Oncology. The consensus contains recommendation on risk assessment, prophylaxis and correction of hyperglycemia regarding the baseline metabolic status of the patients.

Publisher

Consilium Medicum

Subject

Cancer Research,Oncology

Reference13 articles.

1. Стенина М.Б., Жукова Л.Г., Королева И.А. и др. Практические рекомендации по лекарственному лечению рака молочной железы. Злокачественные опухоли. 2020; 10 (3s2). https://rosoncoweb.ru/standarts/RUSSCO/2020/2020-09.pdf [Stenina M.B., Zhukova L.G., Koroleva I.A. et al. Practical recommendations for drug treatment of breast cancer. Malignant Tumors. 2020; 10 (3s2). https://rosoncoweb.ru/standarts/RUSSCO/2020/2020-09.pdf (in Russian).]

2. Alpelisib for the treatment of HR+HER2-metastatic breast cancer in patients with the PIK3CA mutation: results of the SOLAR-1 study

3. Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

4. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

5. Role of PI3K/AKT Pathway in Insulin-Mediated Glucose Uptake

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toxic manifestations of alpelisib in endocrinology. Description of the clinical case;Problems of Endocrinology;2023-09-17

2. <i>PIK3CA</i>-mutated breast cancer: from research to clinical practice;Meditsinskiy sovet = Medical Council;2022-12-07

3. Prevention and correction of alpelisib-induced hyperglycemia (view of endocrinologist);Medical alphabet;2022-07-26

4. Alpelisib therapy: from theory to practice;Meditsinskiy sovet = Medical Council;2022-06-18

5. The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib;Journal of Modern Oncology;2021-12-15